In a retrospective study that assessed CPX-351 efficacy and safety in adults with newly diagnosed, untreated t-AML or AML-MRC in France (n = 103), the CR/CRi rate for adults with FLT3-ITD mutations was 67% (n = 6). Here, FLT3 is linked to acute myeloid leukemia.